The FDA has approved the anticoagulant Brilinta for use in patients with cardiovascular disease.

In a small study, a biotech company has tested its own amyotrophic lateral sclerosis drug.

Scenic Biotech founders and biologists have designed their own functional genomics platform to accurately identify genes that modify a specific disease.

The steroidogenesis inhibitor levoketoconazole has improved laboratory parameters in adult patients with endogenous Cushing's disease.

The World Health Organization expects to receive 2 billion doses of COVID-19 vaccines under the COVAX program in 2021.

Experts believe that GALAPAGOS and GILEAD have managed to make a breakthrough on an experimental autotoxin inhibitor in the field of scleroderma therapy.

Clinical studies on VIR-2218 have shown an effective result in the fight against hepatitis B.

The FDA has assigned an orphan drug status to a drug based on rhenium nanoliposom.

A new class of drugs such as HIF-2α inhibitors is considered as an addition to standard cancer immunotherapy.

Chinese scientists are actively engaged in the development of improved immunomodulators.